Share This Page
Drug Price Trends for NDC 51407-0854
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0854
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0854
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ERYTHROMYCIN BASE 500MG TAB,EC | Golden State Medical Supply, Inc. | 51407-0854-30 | 30 | 90.88 | 3.02933 | 2024-05-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51407-0854
Introduction
The drug identified by the National Drug Code (NDC) 51407-0854 pertains to a specific pharmaceutical product listed for distribution within the US healthcare system. As of the latest available data, the precise formulation, indications, and manufacturer details are critical for understanding its market dynamics, competitive landscape, and future pricing trajectories. This report provides a comprehensive market analysis and price projection, aimed at enabling stakeholders to make strategic decisions in clinical, commercial, and investment contexts.
Product Overview
NDC 51407-0854 corresponds to [Insert drug name and formulation here]. This product is typically indicated for [discuss primary indications, e.g., oncology, autoimmune diseases, chronic conditions]. It is classified as a [biologic, small molecule, biosimilar, etc.], with administration routes including [intravenous, subcutaneous, oral, etc.]. Its clinical positioning is influenced by competitive therapies, approval status, and reimbursement profiles.
(Note: Specific product data such as the exact drug name, manufacturer, and approval status should be integrated here from authoritative sources such as FDA labels, manufacturer disclosures, or authoritative drug databases.)
Market Landscape
1. Market Size and Patient Population
The total addressable market for [drug name] hinges on its approved indications, off-label uses, and the prevalence of the target population. Recent epidemiological studies estimate [relevant disease prevalence] in the U.S., with growth trends projected at [percentage] annually owing to [factors such as aging demographics, increased diagnosis, or new indications].
According to IQVIA’s latest reports, the current market size for therapies targeting [indication] is approximately [$X billion], with forecasts indicating steady expansion driven by [innovations, expanded indications, or increased adoption].
2. Competitive Environment
Key competitors include [list primary competitors: brand-name drugs, biosimilars, generics], each with varying market shares. The existing standard of care comprises drugs such as [competitor drugs], which differ in efficacy profiles, administration routes, and pricing.
Biosimilar and generic entrants are poised to influence price dynamics markedly, especially as patent protections expiry or exclusivity periods lapse. The entry of biosimilars has historically driven price reductions of [range]% within therapeutics’ markets (e.g., monoclonal antibodies), suggesting similar trends could apply here.
3. Regulatory Status and Reimbursement
[Drug name] holds [approval status: FDA approved, orphan designation, etc.]. Reimbursement policies, including Medicaid, Medicare, and private insurers, influence pricing strategies. Outcomes-based agreements and risk-sharing models are increasingly adopted, impacting net pricing and access.
Pricing Trends and Drivers
1. Current Pricing Landscape
Current wholesale acquisition costs (WAC) for comparable drugs range from [$X to $Y] per unit. The initial pricing for [drug name] upon market entry generally reflects a balance between recouping R&D investments and competitive positioning, often situated at [premium/discount] levels relative to incumbents.
Market realities, including payer negotiations and formulary placements, suppress list prices but may result in significantly lower net prices due to rebates and discounts. The overall average selling price (ASP) often trends [downward/stable] in response to biosimilar competition and market saturation.
2. Price Trajectories
Analysts project that [drug name]'s price will follow these trajectories:
-
Short-term (1–3 years): Prices may stabilize around initial launch levels or slightly decline due to payer pressure, with anticipated discounts of [X]% to secure formulary access.
-
Mid-term (3–5 years): Introduction of biosimilars or generics could reduce prices by [Y]% to [Z]%. Furthermore, increased use of value-based contracting could influence effective net prices.
-
Long-term (>5 years): Patents expiry, evolving treatment paradigms, and increased biosimilar penetration could precipitate a sustained price decline of [up to 50]%, paralleling trends seen with similar biologics.
Factors Influencing Future Pricing
Several variables will shape future pricing:
- Regulatory developments: New approvals or label expansions can alter market share and pricing power.
- Market competition: Entry of biosimilars or alternative therapies.
- Reimbursement reforms: Policy shifts favoring value-based pricing and biosimilar adoption.
- Manufacturing costs: Economies of scale and supply chain efficiencies.
- Clinical adoption rates: Physician and patient acceptance significantly impact demand and pricing.
Strategic Implications
Stakeholders should closely monitor [drug name]'s evolving clinical evidence, reimbursement landscape, and competitive actions. Early biosimilar entrants, pricing negotiations, and formulary considerations will be primary drivers of its market valuation and price reductions over time.
The profit outlook hinges on balancing initial high-value pricing with timely market share expansion and competitive positioning. For manufacturers, developing biosimilar or value-added formulations could mitigate downward price pressures.
Key Takeaways
- The current market for [drug name] is characterized by moderate valuation with strong growth potential, contingent upon regulatory status, clinical adoption, and competitive forces.
- Price projections indicate a gradual decline driven by biosimilar competition, formulary negotiations, and evolving reimbursement policies.
- Strategic positioning should focus on demonstrating clinical value, engaging payers early, and exploring biosimilar development to sustain profitability.
- Market expansion opportunities exist through label extensions, geographic expansion, and targeted indications.
Conclusion
The market for NDC 51407-0854 is poised for growth and price evolution influenced by competitive dynamics, regulatory changes, and market acceptance. Stakeholders must employ a multifaceted approach integrating clinical, regulatory, and economic analyses to optimize long-term value.
FAQs
Q1: When is the expected patent expiry for [drug name]?
A1: Patent expiry is projected for [date], after which biosimilar competition is expected to enter the market, impacting pricing.
Q2: How does biosimilar entry typically affect [drug name] prices?
A2: Biosimilar entry generally leads to significant price reductions, often 20–50%, as competition increases and market share redistributes.
Q3: What are the main challenges in projecting future prices for biologics like [drug name]?
A3: Challenges include unpredictable regulatory decisions, speed of biosimilar adoption, payer negotiation strategies, and shifts in clinical practice.
Q4: How do reimbursement policies influence the net price of [drug name]?
A4: Reimbursement policies, including negotiated discounts and formulary placements, heavily impact net prices beyond list prices, often reducing the gross cost paid by payers.
Q5: Are there any upcoming regulatory changes that could impact the market for [drug name]?
A5: Policy initiatives favoring biosimilar reimbursement and value-based care could accelerate price competition and market entry, shaping future dynamics.
References
- IQVIA Institute for Human Data Science. The Changing Landscape of the U.S. Biologic Market. 2022.
- FDA Drug Approvals. [Relevant drug-specific approval announcements].
- Medicare & Medicaid Services. Reimbursement policies affecting biologics.
- Industry reports on biosimilar market entry and pricing trends.
- [Any other authoritative sources used]
Note: Precise product details, clinical data, and market figures should be updated with current proprietary or publicly available sources before decision-making.
More… ↓
